Ranbaxy Laboratories Limited (RLL), has received approval in Canada to manufacture and market tamsulosin hydrochloride capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD). This product has proven to be bio-equivalent to Flomax capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH). The total market for both generic and brand Tamsulosin Hydrochloride capsules in Canada is CAD $22 million.
"We are pleased to receive this approval from TPD for Tamsulosin Hydrochloride capsules that will expand Ranbaxy's expanding product portfolio of accessible and affordable generic product offerings. We are also quite proud of the fact that this formulation was fully developed within our parent company Ranbaxy Laboratories Limited, which further demonstrates the capabilities and competencies of the Ranbaxy organization. This is the fourth product to be added to our product portfolio through this pathway in 2007. RPCI's sales team will be offering Ran-Tamsulosin immediately under the Ranbaxy label in all of the Canadian provinces that now provides another option to pharmacist for this molecule that will be of benefit to both patients and the Canadian Health Care system" said Paul Drake, president, Ranbaxy Pharmaceuticals Canada Inc. (RPCI), Canada.
Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.